Detection of novel mRNA splice variants of human ING4 tumor suppressor gene

Oncogene

Volumn 26, Issue 36, 2007, Pages 5247-5257

  Raho, G ^a   Miranda, C ^a   Tamborini, E ^a   Pierotti, M A ^a,b   Greco, A ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

Alternative splicing; ING4; PHD domain

Indexed keywords

COMPLEMENTARY DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROTEIN P53;

ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPUTER MODEL; CONTROLLED STUDY; ENZYME INHIBITION; GENE ACTIVITY; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAMMAL CELL; NUCLEAR LOCALIZATION SIGNAL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; RNA SPLICING; TUMOR SUPPRESSOR GENE;

BASE SEQUENCE; CELL CYCLE PROTEINS; DNA PRIMERS; DNA, COMPLEMENTARY; GENES, TUMOR SUPPRESSOR; HELA CELLS; HOMEODOMAIN PROTEINS; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA SPLICING; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEINS;

MAMMALIA;

EID: 34547790389     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210335     Document Type: Article

References (33)

1. Bienz M. (2006). The PHD finger, a nuclear protein-interaction domain. Trends Biochem Sci 31: 35-40.
2. Doyon Y, Cayrou C, Ullah M, Landry AJ, Cote V, Selleck W et al. (2006). ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. Mol Cell 21: 51-64.
3. Feng X, Hara Y, Riabowol K. (2002). Different HATS of the ING1 gene family. Trends Cell Biol 12: 532-538.
4. Garkavtsev I, Kozin SV, Chernova O, Xu L, Winkler F, Brown E et al. (2004). The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 428: 328-332.
5. Gong W, Suzuki K, Russell M, Riabowol K. (2005). Function of the ING family of PHD proteins in cancer. Int J Biochem Cell Biol 37: 1054-1065.
6. Gozani O, Karuman P, Jones DR, Ivanov D, Cha J, Lugovskoy AA et al. (2003). The PHD finger of the chromatin-associated protein ING2 functions as a nuclear phosphoinositide receptor. Cell 114: 99-111.
7. Greco A, Mariani C, Miranda C, Lupas A, Pagliardini S, Pomati M et al. (1995). The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain. Mol Cell Biol 15: 6118-6127.
8. Gunduz M, Nagatsuka H, Demircan K, Gunduz E, Cengiz B, Ouchida M et al. (2005). Frequent deletion and down-regulation of ING4, a candidate tumor suppressor gene at 12p13, in head and neck squamous cell carcinomas. Gene 356: 109-117 109-117.
9. Gunduz M, Ouchida M, Fukushima K, Ito S, Jitsumori Y, Nakashima T et al. (2002). Allelic loss and reduced expression of the ING3, a candidate tumor suppressor gene at 7q31, in human head and neck cancers. Oncogene 21: 4462-4470.
10. He GH, Helbing CC, Wagner MJ, Sensen CW, Riabowol K. (2005). Phylogenetic analysis of the ING family of PHD finger proteins. Mol Biol Evol 22: 104-116.
11. Huiping C, Kristjansdottir S, Bergthorsson JT, Jonasson JG, Magnusson J, Egilsson V et al. (2002). High frequency of LOH, MSI and abnormal expression of FHIT in gastric cancer. Eur J Cancer 38: 728-735.
12. Kalnina Z, Zayakin P, Silina K, Line A. (2005). Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer 42: 342-357.
13. Kataoka H, Bonnefin P, Vieyra D, Feng X, Hara Y, Miura Y et al. (2003). ING1 represses transcription by direct DNA binding and through effects on p53. Cancer Res 63: 5785-5792.
14. Kaufmann D, Leistner W, Kruse P, Kenner O, Hoffmeyer S, Hein C et al. (2002). Aberrant splicing in several human tumors in the tumor suppressor genes neurofibromatosis type 1, neurofibromatosis type 2, and tuberous sclerosis 2. Cancer Res 62: 1503-1509.
15. Kim S, Chin K, Gray JW, Bishop JM. (2004). A screen for genes that suppress loss of contact inhibition: identification of ING4 as a candidate tumor suppressor gene in human cancer. Proc Natl Acad Sci USA 101: 16251-16256.
16. Kozak M. (1987). An analysis of 50-nonencoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res 15: 8125-8132.
17. Loewith R, Meijer M, Lees-Miller SP, Riabowol K, Young D. (2000). Three yeast proteins related to the human candidate tumor suppressor p33(ING1) are associated with histone acetyltransferase activities. Mol Cell Biol 20: 3807-3816.
18. Lu F, Dai DL, Martinka M, Ho V, Li G. (2006). Nuclear ING2 expression is reduced in human cutaneous melanomas. Br J Cancer 95: 80-86.
19. Nagashima M, Shiseki M, Miura K, Hagiwara K, Linke SP, Pedeux R et al. (2001). DNA damage-inducible gene p33ING2 negatively regulates cell proliferation through acetylation of p53. Proc Natl Acad Sci USA 98: 9671-9676.
20. Nagashima M, Shiseki M, Pedeux RM, Okamura S, Kitahama-Shiseki M, Miura K et al. (2003). A novel PHD-finger motif protein, p47ING3, modulates p53-mediated transcription, cell cycle control, and apoptosis. Oncogene 22: 343-350.
21. Nouman GS, Angus B, Lunec J, Crosier S, Lodge A, Anderson JJ. (2002). Comparative assessment expression of the inhibitor of growth 1 gene (ING1) in normal and neoplastic tissues. Hybrid Hybridomics 21: 1-10.
22. Okano T, Gemma A, Hosoya Y, Hosomi Y, Nara M, Kokubo Y et al. (2006). Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer. Oncol Rep 15: 545-549.
23. Ozer A, Wu LC, Bruick RK. (2005). The candidate tumor suppressor ING4 represses activation of the hypoxia inducible factor (HIF). Proc Natl Acad Sci USA 102: 7481-7486.
24. Pena PV, Davrazou F, Shi X, Walter KL, Verkhusha VV, Gozani O et al. (2006). Molecular mechanism of histone H3K4me3 recognition by plant homeodomain of ING2. Nature 442: 100-103.
25. Russell M, Berardi P, Gong W, Riabowol K. (2006). Grow-ING, Age-ING and Die-ING: ING proteins link cancer, senescence and apoptosis. Exp Cell Res 312: 951-961.
26. Shi X, Hong T, Walter KL, Ewalt M, Michishita E, Hung T et al. (2006). ING2 PHD domain links histone H3 lysine 4 methylation to active gene repression. Nature 442: 96-99.
27. Shiseki M, Nagashima M, Pedeux RM, Kitahama-Shiseki M, Miura K, Okamura S et al. (2003). p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. Cancer Res 63: 2373-2378.
28. Tsai KW, Lin WC. (2006). Quantitative analysis of wobble splicing indicates that it is not tissue specific. Genomics 88: 855-864.
29. Unoki M, Shen JC, Zheng ZM, Harris CC. (2006). Novel splice variants of ING4 and their possible roles in the regulation of cell growth and motility. J Biol Chem 281: 34677-34686.
30. Venables JP. (2004). Aberrant and alternative splicing in cancer. Cancer Res 64: 7647-7654.
31. Wagner MJ, Helbing CC. (2005). Multiple variants of the ING1 and ING2 tumor suppressors are differentially expressed and thyroid hormone-responsive in Xenopus laevis. Gen Comp Endocrinol 144: 38-50.
32. Zhang X, Wang KS, Wang ZQ, Xu LS, Wang QW, Chen F et al. (2005). Nuclear localization signal of ING4 plays a key role in its binding to p53. Biochem Biophys Res Commun 331: 1032-1038.
33. Zhou MI, Foy RL, Chitalia VC, Zhao J, Panchenko MV, Wang H et al. (2005). Jade-1, a candidate renal tumor suppressor that promotes apoptosis. Proc Natl Acad Sci USA 102: 11035-11040.